Claude Protein Synthesis: 15 Targets Hit Out of 14

Dynamic Folding AI Newsletter: Anthropic enabled Claude to independently complete a round of protein design experiment. Claude Opus 4.8 and Mythos Preview were designed to bind tightly to 15 target proteins, with successful binding achieved for 14 targets.

Of course, Claude did not directly "hand-roll proteins." Researchers plugged it into a suite of protein design and structure prediction tools. Claude itself researched, selected design positions, called upon tools, and continuously filtered and modified proposals, with no human involvement in specific design decisions.

These designs were subsequently subjected to real biological experiments. Adaptyv Bio and Twist Bioscience, two biotech companies, each produced and tested in the laboratory the proteins designed by Claude to see if they could be correctly synthesized and if they could efficiently bind to the target proteins.

Out of the 1320 designs tested, 354 were successful, resulting in a hit rate of approximately 27%. Anthropic stated that this type of protein design usually only achieves a hit rate of about 10% to 15%. Results on some targets even exceeded those of previous protein design competition winners.

However, Claude is still far from developing new drugs on its own. Designing proteins that bind to targets is just one early step in drug development, as extensive experiments and clinical validation are still required.